Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$105.93 USD
-7.27 (-6.42%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $106.01 +0.08 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
JAZZ 105.93 -7.27(-6.42%)
Will JAZZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
Other News for JAZZ
JAZZ: Morgan Stanley Lowers Price Target, Maintains Overweight Rating | JAZZ Stock News
Jazz Pharmaceuticals price target lowered by $30 at Truist, here's why
Jazz Pharmaceuticals (JAZZ) Expects Key FDA Decision Amid Leadership Transition
Jazz Pharmaceuticals plc 2025 Q2 - Results - Earnings Call Presentation
Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance